Tyrosine kinase inhibitors (TKIs) exemplify the success of molecular targeted therapy for
chronic myeloid leukemia (CML). However, some patients do not respond to TKI therapy …

While the clinical impact of mutations in the ABL1 gene on response to therapy in chronic
phase chronic myeloid leukemia (CP-CML) is well established, less is known about how …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative growth of human pluripotent
stem cells which is estimated to occur at a rate of 1/100000 populations every year …

The BCR:: ABL1 gene fusion initiates chronic myeloid leukemia (CML); however, evidence
has accumulated from studies of highly selected cohorts that variants in other cancer-related …

Post-transcriptional methylation modifications, such as the N7-methylguanosine (m7G)
modification, are increasingly acknowledged for their role in the development and resistance …

Background Cell differentiation agent II (CDA-II) exhibits potent anti-proliferative and
apoptosis-inducing properties against a variety of cancer cells. However, its mechanism of …

Chronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disease resulting in
the fusion of BCR and ABL genes and characterized by the presence of the reciprocal …

慢性髓性白血病衍生9号染色体ASS基因缺失与非缺失患者的临床特征 Page 1 肿瘤防治研究
2023年第50卷第3期 Cancer Res Prev Treat,2023,Vol.50,No.3 ·283· doi:10.3971/j.issn.1000-8578.2023.22.0701 …

Breast cancer is one of the most prevalent and diverse malignancies affecting women
worldwide, with an estimated 2.3 million new cases globally in 2020 alone. In Sweden …

Objective (s): Intolerable side effects and resistance to chemotherapeutic drugs have
encouraged scientists to develop new methods of drug combinations with fewer …